Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Post-authorization safety of lenalidomide+dexamethasone in patients with multiple myeloma in Turkey

Meral Beksac • 25 Aug 2022
IMS 2022
Multiple Myeloma Dexamethasone Lenalidomide

Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of the results of a study evaluating the post-authorization safety of the combination of lenalidomide and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma in Turkey, discussing the incidence of venous thromboembolism (VTE), second primary malignancy (SPM), and treatment discontinuation. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Meral Beksac

3:36
Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac • 11 Dec 2023
3:52
EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac • 12 Dec 2023
2:16
The value of the early relapse EBMT score in multiple myeloma
Meral Beksac • 28 Sep 2023
1:30
Exploring the role of upfront autoSCT in multiple myeloma
Meral Beksac • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals